(Q45367066)

English

A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease

scientific article published in August 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

1 reference

based on heuristic

inferred from title

randomized controlled trial

1 reference

based on heuristic

inferred from title

author name string

Timothy F Feltes

1

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Henry M Sondheimer

2

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Robert M R Tulloh

3

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Brian S Harris

4

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Kathryn M Jensen

5

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Genevieve A Losonsky

6

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

M Pamela Griffin

7

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Motavizumab Cardiac Study Group

8

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

language of work or name

0 references

publication date

1 August 2011

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Pediatric Research

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

70

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

186-191

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

https://scigraph.springernature.com/pub.10.1203/pdr.0b013e318220a553

0 references

Bronchiolitis-associated hospitalizations among US children, 1980-1996.

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318220A553

21 January 2018

Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318220A553

21 January 2018

Neonatal respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318220A553

21 January 2018

From the National Institute of Allergy and Infectious Diseases and the World Health Organization. Respiratory syncytial and parainfluenza viruses

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318220A553

21 January 2018

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318220A553

21 January 2018

From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318220A553

21 January 2018

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318220A553

21 January 2018

Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318220A553

21 January 2018

Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318220A553

21 January 2018

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318220A553

21 January 2018

Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318220A553

21 January 2018

Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318220A553

21 January 2018

Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318220A553

21 January 2018

Epidemiologic programs for computers and calculators. Exact binomial confidence intervals for the relative risk in follow-up studies with sparsely stratified incidence density data

1 reference

https://api.crossref.org/works/10.1203%2FPDR.0B013E318220A553

21 January 2018

Identifiers

10.1203/PDR.0B013E318220A553

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45367066&oldid=2075895585"